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Abstract
MUC1 is a transmembrane glycoprotein that modulates transcription via its cytoplasmic domain. We evaluated the
capacity of MUC1 to regulate the global transcription of microRNAs in pancreatic cancer cells expressing MUC1.
Results indicated that MUC1 regulated expression of at least 103 microRNAs. We evaluated further regulation of the
microRNA transcript cluster miR-200c/141, which was among the most highly regulated microRNAs. We found that
MUC1 directly interacted with ZEB1, a known transcriptional repressor of the miR-200c/141 cluster, at the promoter
of miR-200c/141, and further reduced transcript production. These data indicate that signaling through MUC1
influences cancer progression by regulating transcription of microRNAs that are associated with the process of
metastasis.
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Introduction

MUC1.CT to associate with distinct transcription factors,
including β-catenin, p120 catenin, γ-catenin, c-Jun, p53, and
ER-α, which, in turn, regulate transcription of multiple genes
including MMP1 and CTGF, among others [6,7].
We examined the effects of MUC1 overexpression on global
patterns of microRNA (miR) expression in pancreatic tumors,
and report here alterations in expression of numerous
microRNAs that are associated with cellular processes of tumor
progression. MicroRNAs are small regulatory RNAs, 19-23
nucleotides in length, which regulate protein expression by
binding to the 3’UTR of mRNA target transcripts. MicroRNAs
function by inhibiting translation of the protein (nonhomologous binding), or by acting as siRNAs (highly
homologous binding), which target mRNAs for degradation.
MicroRNAs are differentially expressed in cancer compared to
healthy tissue, where they contribute to tumorigenesis.
We observed an inverse correlation between miR-200c
expression and expression of MUC1, and further evaluated the

Mucin 1 (MUC1) is present at the apical surface of normal
epithelial cells and tumors cells, where it establishes a local
extracellular microenvironment and acts as a sensor of the
extracellular environment [1]. The carboxyl terminal domain of
MUC1 (MUC1.CT) interacts with and is differentially
phosphorylated by receptor tyrosine kinases and other serine
and threonine kinases [2], which in turn induces its association
with transcription factors, translocation to the nucleus and
localization at different promoters, where it modulates gene
expression [3–7]. Signaling through MUC1 via the C-terminal
domain (MUC1.CT) modulates transcriptional programs related
to epithelial cell biology [2]. Stimulation of the MET receptor
with HGF induces phosphorylation of the tyrosine at YHPM,
while stimulation of EGFR induces phosphorylation of the
tyrosine at YEKV, and PDGFR phosphorylates tyrosines at
YVPP and YHPM [5,6]. Differential phosphorylation allows the
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examine: the 4 most down-regulated microRNAs (miR-200c,
-141, -192 and -33b); downregulated miR-192 family members
(miR-194 and 215, which have been identified as p53regulated microRNAs); and miR-376c which had been linked to
invasion and metastasis. We also evaluated expression of the
most highly overexpressed microRNA identified, miR-130a,
and another well-known p53-regulated microRNA that was up
regulated in the array, miR-34a. MiR-200a was evaluated as a
control that was not determined to be differentially expressed
on the microRNA microarray, yet related to the miR-200c/141
cluster. We confirmed that levels of the miR-200c/141
transcript were significantly reduced in S2.013.MUC1overexpressing cells (Figure 1a). Levels of known p53regulated family members, miRs-192/194/215, were also
significantly down regulated in S2.013.MUC1 cells, as well as
miR-33b and miR-376c. We confirmed that miR-130a and
miR-34a were up-regulated in these cells, although expression
of miR-34a did not achieve statistical significance in
S2.013.MUC1 cells. Interestingly, levels of another miRNA-200
family member that is separately encoded, miR-200a, were
unchanged in S2.013.MUC1 cells.
We evaluated expression of these microRNAs in a second
pancreatic cancer cell line model system of MUC1
overexpression (Panc1) by quantitative RT-PCR. Similar to
S2.013.MUC1 cells, miR-200c was down regulated in
Panc1.MUC1 cells compared to Panc1.Neo (Figure 1b);
however, we did not observe alterations in the levels of
miR-141 that is encoded at the same locus. We found that
miR-194 was similarly down regulated in the Panc1.MUC1
cells, while miRs-192 and -215 were not altered. Mir-130a was
also not significantly altered, but there was an up regulation of
miR-34a in Panc1.MUC1 cells. Interestingly, miR-376c showed
a dramatic and significant increase in the Panc1.MUC1 cells,
whereas it was down regulated in S2.013.MUC1 cells.

Table 1. Top 10 differentially expressed microRNAs in
S2.013.MUC1 versus S2.013.Neo.

microRNA

Fold Change (log2)

hsa-miR-200c

-8.650552179

hsa-miR-141

-7.231312952

hsa-miR-192

-3.587380659

hsa-miR-33b

-3.502024284

hsa-miR-135b

-3.483740762

hsa-miR-1224-3p

2.378295683

hsa-miR-218

3.137032348

hsa-miR-146a*

3.800029169

hsa-miR-27b*

4.15437337

hsa-miR-130a

4.611699725

doi: 10.1371/journal.pone.0073306.t001

regulation behind this correlation. MiR-200c regulates a
number of proteins associated with epithelial cell differentiation
and
processes
associated
with
progression
of
adenocarcinomas [8–11]. Given that MUC1 is known to
regulate transcription of a number of processes associated with
tumor progression, we hypothesized that transcription of
miR-200c was regulated by signal transduction through MUC1.
Both MUC1 and miR-200c have been associated with tumor
progression and epithelial to mesenchymal transition (EMT).
EMT is a process in which cells loose cellular contacts, through
loss of E-cadherin, thus making them mobile to allow for
migration and metastasis. Previous studies have depicted
miR-200c as a regulator of EMT by targeting ZEB1, a
transcriptional repressor of E-cadherin. ZEB1 also negatively
regulates miR-200c; therefore they form a feed-forward loop to
stabilize EMT [12]. We report here that miR-200c is regulated
by specific phosphorylated forms of MUC1 through direct
interaction with ZEB1 at the promoter of miR-200c/141
microRNA cluster.

Levels of miR-200c and MUC1 in human pancreatic
tumors
We evaluated levels of miR-200c in specimens of primary
and metastatic human pancreatic tumors. RNA was isolated
from multiple tumors and adjacent uninvolved tissue (tissue
that was from the same cancer patient, but lacking tumor)
(Figure 1c). These data show that miR-200c levels significantly
decrease between primary tumor and metastases to the lung
and lymph nodes, but not to the liver. Levels of miR-200c
increase in liver metastases, compared to uninvolved liver.
These data indicate that expression of miR-200c is maintained
but differentially regulated during tumor progression and
metastasis.

Results
Differential microRNA expression with MUC1
We utilized miRCURY LNA microarrays (Exiqon) to evaluate
expression of microRNAs in the context of MUC1
overexpression in pancreatic cancer cells. We examined
S2.013 pancreatic cancer cells, with and without
overexpression of MUC1, and identified 103 microRNAs
altered by MUC1 expression (Table S1). These microRNAs are
known and predicted to impact multiple cellular functions that
are associated with tumor progression, including proliferation,
apoptosis,
senescence,
metabolism,
resistance
to
chemotherapy, angiogenesis, and EMT (Table S2). The top
five up- and down-regulated microRNAs are shown in Table 1.

MUC1.CT occupancy at the promoter region of
miRNA-200c/141
The cytoplasmic tail of MUC1 (MUC1.CT) engages in signal
transduction by translocating to the nucleus, where it alters
gene expression by associating with and modifying the activity
of transcription factors [3–7]. To further investigate the role of
MUC1 in regulating the levels of the miR-200c/141 transcript,
we utilized chromatin immunoprecipitation (ChIP). ChIP-onchip data indicated that the MUC1.CT localized to the promoter

qRT-PCR confirmation of microRNA levels in a subset
of microRNAs
Quantitative, real time RT-PCR was used to confirm
alterations of microRNA expression for a subset of microRNAs
that were identified by microarray analysis. We chose to
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Figure 1. qRT-PCR confirmation of microRNA levels in cells and pancreatic cancer tissue. MicroRNA levels were evaluated
in triplicate by qRT-PCR to confirm expression changes identified by microarray analysis (Table 1). MicroRNA levels were
normalized to the U6 RNA control. A) MiRs-200c, -141, -192, -33b, -194, -215, and -376c expression levels were evaluated in
S2.013.Neo compared to S2.013.MUC1 cells. B) MiRs-200c, -141, -192, -33b, -194, -215, and -376c expression levels were
evaluated in Panc1.Neo and Panc1.MUC1 cells. C) Levels of miR-200c were evaluated in a panel of pancreatic cancer tissues.
These data are represented by Ct value, where lower Ct values indicate higher levels of miR-200c, and each data point represents
a different patient sample. Uninvolved tissue is non-cancerous tissue isolated from a cancer patient. (Student’s t-test: *** p < 0.0005,
** p < 0.005, * p < 0.05).
doi: 10.1371/journal.pone.0073306.g001
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of miR-200/141 (Figure 2a). The region of the miR-200c/141
promoter bound by the MUC1.CT also contains the known
ZEB1 binding domain, a known transcriptional repressor of
miR-200c. Figure 2a presents a schematic showing the
upstream promoter region of the miR-200c/141 transcript,
indicating the ZEB1 binding region (depicted as a grey bar).
Primers were designed flanking the promoter region bound by
MUC1.CT, as well as a control region (-480 to -210 and +552
to +675, respectively) (Figure 2a). Previous reports have
shown that MUC1.CT stabilizes transcription factor occupancy
of promoter regions [3,4,6,7,13]. Therefore, we explored in
detail the capacity of MUC1.CT to occupy the ZEB1 binding
region of the miR-200c/141 locus. ChIP data indicated that
MUC1.CT occupied the promoter of miR-200c/141 that
contains the ZEB1 binding region (Figure 2b). We therefore
examined levels of ZEB1 at the promoter region. These data
confirm ZEB1 occupancy at the miR-200c/141 promoter, and
show that increased levels of MUC1 correspond to an increase
in ZEB1 at the same sites in the promoter by approximately
3.5-fold (Figure 2c).

present in complexes in S2.013.MUC1 cells (Figure 3a). We
also show an increase in steady state ZEB1 levels in
S2.013.MUC1 cells, most likely do to the loss of miR-200c and
the feed-forward loop that is initiated by down regulation of
miR-200c. To further quantify the MUC1.CT interaction with
ZEB1, we employed the proximity ligase assay (PLA), which
detects in-cell protein-protein interactions as punctate spots
that can be quantified and associated with sub-cellular
localization. Figure 3b shows quantitative PLA results in the
S2.013.Neo and S2.013.MUC1 cell lines as well as a
representative compressed z-stack image of the assay. The
results of this assay support the co-immunoprecipitation results
and demonstrate that MUC1.CT and ZEB1 are colocalized in
the cell, at significantly higher levels in the S2.013.MUC1 cells
compared to the S2.013.Neo cells. We also evaluated the
interaction in Panc1.Neo and Panc1.MUC1 cells and
demonstrate that MUC1.CT and ZEB1 interact at similar levels
in Panc1.Neo and Panc1.MUC1 cells (Figure 3c). Interestingly,
in both the S2.013 and Panc1 cells the interaction occurs in
both the nucleus and the cytoplasm.

Specific phosphorylated form of MUC1.CT localize to
the miR-200c promoter

MiR-200c levels in a panel of pancreatic cancer cell
lines, primary tumors and liver metastases

Multiple reports have shown a link between EGFR signaling
and E-cadherin (downstream molecule of miR-200c regulation)
loss [14–18], therefore, we investigated the contribution of
EGFR signaling through MUC1 to the loss of miR-200c.
Phosphorylation of MUC1.CT can occur through multiple
receptor tyrosine kinases that mediate signaling events,
including HGF, MET, PDGF, and EGF [2,5,6]. We evaluated
levels of specific phosphorylated forms of MUC1.CT that were
localized to the miR-200c/141 promoter. Three antibodies
against specific tyrosine-phosphorylated forms of MUC1.CT
were used, recognizing the pYHPM, pYVPP, and pYEKV forms
of MUC1.CT, which are phosphorylation events that have been
shown to be mediated by HGF/c-met, PDGF, and EGF,
respectively [5,6,19] (Figure 2d). The pYEKV form of MUC1.CT
localized to the ZEB1 binding region of the miR-200c promoter
in the S2.013.MUC1 cell line, while the pYHPM and pYVPP
forms are not detected at this region (Figure 2e). A second
pancreatic
cancer
cell
line
overexpressing
MUC1,
Panc1.MUC1, was investigated for phospho-MUC1.CT
occupancy at the miR-200c/141 promoter. We demonstrate
that pYEKV MUC1.CT is present at the miR-200c/141 locus in
Panc1.MUC1 cells (Figure 2f). These data suggest that EGF
phosphorylation of MUC1.CT at YEKV is a principal signaling
pathway through which MUC1 regulates levels of
miR-200c/141 in this experimental system.

To further evaluate miR-200c expression in pancreatic
cancer cell lines, we assayed a panel of 8 pancreatic cancer
cell lines, as well as a normal, immortalized nestin-expressing
pancreatic cell line (HPNE). MiR-200c levels were evaluated in
these cells (Figure 4a) and evaluated against MUC1.CT
expression (based on western blot, data not shown). MiR-200c
levels in these cell lines correlated to differentiation status of
the cell lines. Undifferentiated cell lines such as Hs766t, Panc1,
and HCG25 have relatively low levels of miR-200c. Moderately
differentiated cell lines such as AsPC-1, SUIT-2 and HPAF
have moderate levels of miR-200c. Well-differentiated cell lines
such as CFPAC-1 and Capan2 have higher levels of miR-200c.
We also evaluated levels of MUC1.CT in these cells, depicted
with the black bar and using the right y-axis. There was no
direct correlation between MUC1 levels and loss of miR-200c
in these cell lines.
We extended this analysis to matched sets of primary
pancreatic tumors and metastases. Immunohistochemical
staining was previously performed on tissue sections from
matched patients and scored on a 1-3 scale, where 1
represents low MUC1 levels, and 3 represents high levels of
MUC1 [20]. These matched patient samples from the primary
tumor (Figure 4b) or liver metastasis (Figure 4c) are displayed
in side by side panels. These data also show there is not a
direct correlation between MUC1 expression and miR-200c
levels, confirming data found in the pancreatic cancer cell line
panel. Thus, taken together, these results demonstrate that
MUC1 is not the sole regulator of miR-200c levels but that
instead it modulates levels within the context of broader
regulatory programs.

MUC1.CT directly interacts with ZEB1 transcription
factor
Activated forms of MUC1 directly alter transcription factor
occupancy of promoters [2,7]. Therefore, we used coimmunoprecipitation to determine if the MUC1.CT directly
interacted with ZEB1. An antibody against the cytoplasmic tail
of MUC1 (CT2), and control IgG, were used for
immunoprecipitation, and a subsequent immunoblotting with an
antibody against ZEB1 showed that MUC1.CT and ZEB1 are

PLOS ONE | www.plosone.org

MUC1.CT and ZEB1 interaction in mitotic cells versus
non-mitotic cells
An incidental finding was noted in our analysis of PLA data in
proliferating cells. Cells undergoing mitosis had significantly
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Figure 2.
Chromatin Immunoprecipitation confirmation of MUC1.CT and ZEB1 occupancy of the miR-200c/141
promoter. Chromatin immunoprecipitation (ChIP) was utilized to confirm MUC1.CT and ZEB1 occupancy at the miR-200c/141
promoter region. A) Schematic representing the miR-200c/141 promoter region where the ChIP primer sets were designed (-480 to
-210, and +552 to +675) and the known ZEB1 binding region (Grey bar). B) ChIP results indicate fold change of normalized relative
levels of MUC1.CT occupancy at the ZEB1 binding region (based on qPCR) of the miR-200c/141 promoter in S2.013.MUC1 cells
compared to S2.013.Neo cells. C) ChIP results indicate fold change of normalized relative levels of ZEB1 occupancy at the ZEB1
binding region (based on qPCR) of the miR-200c/141 promoter in S2.013.MUC1 cells compared to S2.013.Neo cells. D) Sequence
of the MUC1 cytoplasmic tail, indicating three phosphorylated tyrosine motifs that were examined here. E-F) ChIP results indicate
relative levels (based on qPCR and normalized to IgG control) of phospho-YHPM, -YVPP, and -YEKV MUC1 cytoplasmic tail at the
ZEB1 binding region of miR-200c/141 in the S2.013.MUC1 cells, E, and Panc1.MUC1 cells, F. In both cell lines, only the phosphoYEKV form of MUC1.CT shows significant enrichment at the promoter. All ChIP data was normalized to antibody specific IgG
control. (Student’s t-test: *** p < 0.0005, ** p < 0.005, * p< 0.05).
doi: 10.1371/journal.pone.0073306.g002
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Figure 3. MUC1.CT directly interacts with transcriptional repressor ZEB1. A) Co-immunoprecipitation (Co-IP) was utilized to
evaluate the interaction of the MUC1.CT and ZEB1 in S2.013.Neo and S2.013.MUC1 cells. Cell lysates were immunoprecipitated
with an antibody against the MUC1.CT, and the subsequent western was blotted with an antibody to ZEB1. Non-immunoprecipitated
lysates were used as a loading control, and steady state levels of ZEB1 were higher in S2.013.MUC1 cells compared to S2.013.Neo
cells. B-C) Proximity ligation assay (PLA) was used to visualize MUC1.CT and ZEB1 interaction in S2.013.Neo and S2.013.MUC1
cells, B, and Panc1.Neo and Panc1.MUC1 cells, C (with representative compressed z-stack image for each). These data show
quantitative levels of MUC1.CT and ZEB1 interactions, indicating that MUC1.CT and ZEB1 interact in both cell lines. In the
S2.013.Neo and S2.013.MUC1 cell lines, the interaction was significantly higher in the MUC1 expressing cells, confirming the Co-IP
in A. However, there was no significant difference in interaction in the Panc1.Neo and Panc1.MUC1 cells. (Student’s t-test: *** p <
0.0005).
doi: 10.1371/journal.pone.0073306.g003
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Figure 4. MiR-200c and MUC1 levels in a panel of pancreatic cancer cell lines and tumor samples. Correlation between
levels of MUC1 and miR-200c in a panel of pancreatic cancer cell lines and a panel of primary tumor sections and liver metastases.
A) MiR-200c levels, indicated by Ct value, are the white bars and correspond to the left y-axis. MUC1 statuses of these cell lines,
determined by western blot, are represented in the black bars and right y-axis. Levels of miR-200c and their corresponding MUC1
levels [20], on the left and right y-axis respectively were evaluated in primary pancreatic tissue (B) and liver metastases (C). MUC1
status was determined based on IHC staining from one section per patient; therefore standard deviation was not determined.
doi: 10.1371/journal.pone.0073306.g004
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Figure 5. PLA analysis of MUC1.CT interaction with ZEB1 in mitotic cells. Proximity ligation assay of MUC1.CT with ZEB1
was analyzed in mitotic cells versus non-mitotic cells. A) PLA results from mitotic (circled) or non-mitotic cells in S2.013.Neo or
S2.013.MUC1, B indicate a roughly 2-3-fold increase in MUC1.CT and ZEB1 interaction. In addition, this interaction occurs mainly in
the cytoplasm, not in the nuclei. (*** p < 0.0005).
doi: 10.1371/journal.pone.0073306.g005

cells. MicroRNAs that were down regulated by MUC1
overexpression modulate expression of proteins that contribute
to the aggressive biological features of pancreatic cancer,
including proliferation, apoptosis, senescence, metabolism,
resistance to chemotherapy, angiogenesis, and epithelial to
mesenchymal transition (Table S2). Both microRNAs of the
miR-200c/141 transcript are reported to be down regulated in
cancer and to play a role in invasion and metastasis [9,10,21].
MiR-192, and its family members miR-194/215, (known p53regulated microRNAs) are reported to be down regulated in
several cancer studies and may play a role in modulating

more MUC1.CT/ZEB1 interactions compared to their nondividing counterparts (Figures 5a and b). Quantified PLA shows
an approximate 2 to 3-fold increase in MUC1.CT:ZEB1
interaction in mitotic cells (circled cells) compared to the nonmitotic cells in each field.

Discussion
We demonstrate here that overexpression of MUC1 and
concomitant signaling through phosphorylation of the
MUC1.CT alters the microRNA profile in pancreatic cancer
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broader regulatory pathways. Regulation through MUC1 is
dependent on signaling, as evidenced by our pYEKV ChIP
results. Thus, this phosphorylated form of MUC1.CT (linked to
EGFR signaling) is responsible for establishing a threshold for
ZEB1 and MUC1.CT interaction. Overall, we find that the
mechanism of MUC1 regulation of the miR-200c/141 cluster is
through phosphorylation of the YEKV motif, which promotes an
EMT phenotype by regulating miR-200c through interacting
with ZEB1. We noted a correlation between miR-200c
expression and differentiation status of the pancreatic cancer
cell lines tested, in which miR-200c expression was increased
in cell lines with higher grades of differentiation. We also note
that endogenous MUC1 levels follow a similar pattern.
We also report an incidental finding, in which dividing cells
have a 3-fold higher level of MUC1.CT:ZEB1 interactions. Few
reports have indicated ZEB1 in conjunction with cellular
proliferation. Liu et al showed that in MEFs from ZEB1 mutant
mice, cells underwent dose dependent premature senescence
[34]. Ahn et al identified that ZEB1 can regulate ∆Np63, a
regulator of miR-34a in a mouse model of lung
adenocarcinoma. This down regulation of miR-34a is then
responsible for pro-metastatic actin cytoskeleton remodeling
[35]. These reports, however, focus on ZEB1 as a transcription
factor. Most transcription factors are displaced during
chromatin condensation in mitosis [36], which accounts for the
localization of MUC1.ZEB1 interaction we observe, however it
does not account for the increase in interaction. This increase
in interaction occurs at the same rate in all dividing cells,
without regard to MUC1 levels, which indicates it may be a
normal mechanism in dividing cells, and should be further
evaluated. It is notable that previous reports have shown that
MUC1 can influence cell cycle, and this observation may be
related to this effect [37].
In summary, our study provides evidence that MUC1
modulates microRNA levels to aid in cancer progression and
metastasis. Signaling through the MUC1 cytoplasmic tail allows
for known transcription factor interactions, as well as a novel
interaction described here, with ZEB1. We also confirm and
extend knowledge of a novel link between MUC1 signaling and
EMT, through regulation of the transcription of miR-200c/141.

proliferation and invasion [22–25]. A recent report from Croce
et al. identified miRs-200c, -141, -192, -194, and -215 (and
other microRNAs) to be upregulated by wild-type p53 [26]. Our
study suggests that MUC1.CT alters transcriptional regulation
of these miRNAs independent of wildtype p53, as both of the
cell lines examined here expressed mutant p53. This suggests
that MUC1 interacts with other transcription factors to alter
expression miR levels, such as ZEB1 at the miR-200c/141
promoter. MiR-33b regulates fatty acid oxidation and insulin
signaling [27], and therefore may play a role in tumor
metabolism. MiR-33b was recently characterized in multiple
myeloma as a tumor suppressor through targeting PIM-1, an
oncogene [28]. MiRNA-130 was found to be up regulated by
MUC1, and is increased in non-small cell lung cancer (NSCLC)
and associated with metastasis and poor prognosis [29] and
chemotherapy resistance to cisplatin [18]. MiR-376 has been
implicated in cell survival in ovarian cancer [30]. However, in
melanoma miR-376c contributed to progression and metastasis
[31]. Interestingly, miR-376c was not consistently regulated
between the two cell lines evaluated here, in S2.013.MUC1
cells miR-376 is lost and in Panc1.MUC1 cell line, miR-376c is
highly overexpressed. Further evaluation of miR-376c in these
cell lines would prove informative in both the regulation of the
microRNA (what factors other than MUC1 are playing a role) as
well as the functional output (what genes it targets in each cell
line). Overall, we show that microRNAs regulated by MUC1
have the potential to influence proliferation, invasion,
metastasis, tumor metabolism, and drug resistance.
We previously reported in an abstract and poster
presentation that signaling through the MUC1.CT is a potent
regulator of miR-200c/141 transcription through interactions
with Zeb1 [32]. As we were preparing the final version of this
manuscript for submission, an independent report appeared
[33] showing results that are consistent with our findings with
respect to MUC1 regulation of miR-200c . Our results
presented here and those of Rajabi et al [33] present evidence
that MUC1.CT binds to the transcriptional repressor ZEB1 and
regulates expression of miR-200c. We extend those findings by
showing that specific phosphorylated forms of MUC.CT were
localized to the ZEB1 binding motif upstream of the
miR-200c/141 start site in two independent cell lines. Similar to
Rajabi et al, our data suggest that signaling through MUC.CT
enables its association with ZEB1 and establishes a feedforward loop that enhances steady state levels of ZEB1 by
repressing miR-200c. We observed that there was an increase
in ZEB1 protein levels in S2.013.MUC1 cells (Figure 3a), which
is also consistent with the report by Rajabi et al. We also found
that an increase in MUC1.CT and ZEB1 interactions in the
S2.013 cell line, but not the Panc1 cell line.
We sought to determine if there were correlations between
miR-200c and relative levels of MUC1 expressed by pancreatic
cancer cell lines, primary tumors and matched metastatic
lesions. Here we report that there was not a correlation
between relative levels of MUC1 and miR-200c in a panel of
pancreatic cancer cell lines or matched sets of primary tumor
and metastases. We interpret these data to suggest that MUC1
is not the sole determining factor that establishes levels of
miR-200c, but rather that it modulates levels in the context of

PLOS ONE | www.plosone.org

Materials and Methods
Ethics Statement
This research was performed with cell lines that are
publically available and with de-identified patient material
obtained from deceased patients upon rapid autopsy.
Specimens from patients with pancreatic cancer were obtained
with written consent and IRB approval IRB 091-01-FB at the
University of Nebraska Medical Center through the Rapid
Autopsy Program (RAP).

Cell culture
S2.013 pancreatic cancer cells have previously been
described [38], and Panc1 cancer cells were obtained from
American Type Culture Collection. Stable expression of MUC1
(flag-epitope tagged) in Panc1 (Panc1.MUC1) and S2.013
(S2.013.MUC1) has previously been described [3] and resulted
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Co-immunoprecipitation

in robust expression of MUC1 (Figure S1). All cells were grown
in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum, 200 μg/mL G418, and ciprofloxacin. Cells
were cultured and maintained in a humidified chamber at 37°C
with 5% CO2.

Nuclear lysates were prepared by lysing cells using a
hypotonic/hypertonic lysis method. Cells were scraped into a
hypotonic buffer (10 mM Hepes pH 7.9, 10 mM KCl, and 0.1
mM EDTA) to lyse the cells, while leaving the nuclei intact.
Centrifugation at 6,000 x g for 2 minutes was used to collect
the nuclei. The supernatant was kept for the cytosolic fraction
and the pelleted nuclei were washed twice with hypotonic
buffer. Hypertonic lysis buffer (20 mM Hepes pH 7.9, 0.4 M
NaCL, and 1 mM EDTA) was added to lyse the nuclei. This
fraction was centrifuged at 16,000 x g for 5 minutes to remove
cell debris from the nuclear lysates. These buffers were
supplemented with 0.1 mM PMSF and complete protease
inhibitor
tablet
(Roche
Diagnostics,
USA).
Coimmunoprecipitations were performed with 2 μg CT2 antibody
and an isotype-matched IgG as control.

RNA Isolation and Quantitative Real-time PCR
RNA was isolated from S2.013 and Panc1 cells (either
MUC1- or Neomycin-expressing) using the mirVana miRNA
Isolation Kit (Life Technologies, USA) according to
manufacturer’s protocol for total RNA extraction. RNA was
quantified using a NanoDrop100 spectrophotometer. TaqMan
MicroRNA Reverse Transcription Kit (Life Technologies, USA)
was used to generate cDNA. TaqMan human MicroRNA
assays (Life Technologies, USA) were used to quantify levels
of microRNAs and normalized to RNU6b snRNA, according to
manufacturer’s protocol, or represented by Ct value. Briefly, 5
ng (S2.013) or 8 ng (Panc1) total RNA was used for the
reverse transcription assay and 1.33 μL of this reaction was
used for the quantitative real-time PCR assay, in triplicate.

Chromatin Immunoprecipitation and Real-time PCR
analysis
Chromatin immunoprecipitations were performed according
to a protocol adapted from Affymetrix. Briefly, 5.0x107 cells
were washed in 1XPBS and incubated in 5mM dimethyl 3,3’dithiobispropioimidate (DTBP, Pierce Biotechnology) for 30
minutes at 4°C. Cells were rinsed and incubated in 1% HPLCgrade formaldehyde (Sigma) for 10 minutes at room
temperature. Crosslinking reactions were quenched with 2.5M
glycine for 5 minutes. Cells were lysed in ChIP Lysis Buffer
(10mM Tris-HCl pH 7.5, 10mM NaCl, 3mM MgCl2, 0.5%
IGEPAL, 1mM PMSF). Nuclei were collected and sonicated in
Pre-IP Dilution Buffer (10mM Tris-HCl pH 7.5, 10mM NaCl,
3mM MgCl2, 1mM CaCl2, 4% IGEPAL, 1mM PMSF) at duty
cycle 60% and amplitude 50% with 1-minute pulses followed by
1 minute rests. Equal amounts of chromatin were
immunoprecipitated with specific antibodies as indicated or IgG
isotype control in the presence of protease and phosphatase
inhibitors. Chromatin was diluted in 5 volumes of IP Dilution
Buffer (20mM Tris-HCl, 2mM EDTA, 1% Triton X-100, 150 mM
NaCl) with protease and phosphatase inhibitors. 10 ug
antibody was added to chromatin and incubated rotating
overnight at 4°C. 200 ul Protein G Sepharose bead slurry
(Sigma) was added to immune complexes and incubated for 3
hours with rotation at room temperature. Bead-antibodyantigen complexes were washed with successive washes of
ChIP Wash 1 (20mM Tris-HCl pH 8.0, 2mM EDTA, 1% Triton
X-100, 150 mM NaCl), ChIP Wash 2 (20mM Tris-HCl pH 8.0,
2mM EDTA, 1% Triton X-100, 0.1% SDS, 500 mM NaCl) and
ChIP Wash 3 (10mM Tris-HCl pH 8.0, 1mM EDTA, 0.25M LiCl,
0.5% IGEPAL, 0.5% deoxycholate) with protease and
phosphatase inhibitors. Immunoprecipitates were eluted in
Elution Buffer (25mM Tris-HCl pH 7.5, 10mM EDTA, 0.5%SDS)
and decrosslinked with 100mM DTT and 1 ug/ul Proteinase K
at 65°C overnight. Decrosslinked chromatin was purified using
Qiaquick PCR Purification Kit (Qiagen) and subjected to real
time PCR analysis. 3.0 uL chromatin was prepared in Sybr
green master mix (Applied Biosystems) and subjected to
quantitative real-time PCR analysis using ABI 7500
thermocycler. Each reaction was repeated in triplicate and the
experiments were repeated at least twice to confirm

RNA isolation from pancreatic cancer tissue
Specimens from patients with pancreatic cancer were
obtained with written consent and IRB approval IRB 091-01 at
the University of Nebraska Medical Center through the Rapid
Autopsy Program (RAP). Specimens were obtained within 3
hours post-mortem to ensure minimal RNA degradation.
Samples were either flash frozen in liquid nitrogen or placed
directly in formalin fixative for paraffin embedding. Frozen
tissues from primary pancreatic tumors, liver, lung and lymph
node metastases, as well as uninvolved tissue from these sites
were utilized for RNA isolation. We also obtained normal
pancreas samples from non-cancer patients from the UNMC
Tissue Sciences Facility. Frozen specimens were placed in
liquid nitrogen and ground to a fine powder with a sterilized
mortar and pestle (without thawing), and immediately placed in
the mirVana microRNA lysis buffer. RNA isolation was then
completed according to manufacturers protocol as stated
above.

MicroRNA microarray
MiRCURY LNA microarrays (Exiqon, Denmark) were used
according to manufacturer protocol. Briefly, RNA isolated from
S2.013.Neo and S2.013.MUC1 cells was labeled with either
Hy3TM or Hy5TM, hybridized to the array slide, and subsequently
washed. The arrays were then scanned and analyzed using
GenePix Pro 6 (Molecular Devices, USA). The array files were
read in and preprocessed by background correction, withinarray normalization through Loess normalization. The
normalized data was used to obtain values for the differential
expression between samples. For each cell line, microRNAs
with average intensity values lower than the 5th percentile
average intensity values of the arrays were filtered out.
MicroRNAs with at least 2-fold change were designated as
differentially expressed. These data were deposited in Gene
Expression Omnibus, Accession number GSE48185.
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1.0% IGEPAL, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM
Tris, pH, 8.0). Westerns were run with approximately 50 µg
total protein on 10% Bis-Tris gel (Life Technologies, USA), and
transferred to a nylon membrane. Membranes were blocked in
5% non-fat dried milk with 1% TBST, and incubated with CT2
antibody (1:500) for 3 hours, and secondary antibody for 1 hour
at room temperature. Levels of MUC1.CT were designated a
number value from 0-3 depending on their levels.

reproducibility. Values were obtained for the threshold cycle
(Ct) for each gene and data were analyzed using the standard
curve method. Values were normalized to enrichment of a
genomic region within a housekeeping gene (β-glucuronidase,
GUSB). GUSB validated primer pair was purchased from
SABiosciences.
Values are reported as enrichment relative to IgG ChIP, +/SEM. Oligonucleotide sequences for detection of miR-200c
regulatory regions are presented in Table S3. GUSB validated
primer pair was purchased from SABiosciences.

Statistical analysis
Statistical analysis was performed using GraphPad Prism
statistical software. A two-tailed student’s t test was used to
determine significance. p < 0.05 was considered significant.

Proximity Ligation Assay
Reagents for the proximity ligation assay (PLA) were
purchased from Olink (Sweden). PLA provides evidence for
protein-protein interactions directly in cells by detecting their
proximity. Primary antibodies against two proteins of interest
generated in different species are added to the cells.
Secondary
antibodies
(probes)
are
conjugated
to
complimentary DNA sequences, that when in close proximity
(>40nm) anneal to form circular DNA. Amplification of this
circular DNA template with flourescent probes results in
punctate spots for each protein-protein interaction. PLA was
preformed according to manufacturer protocol. Briefly, cells
were seeded overnight on 12 mm poly-L-lysine coated
coverslips in a 12-well plate. The next day cells were washed
twice with PBS, fixed with 4% paraformaldehyde with 120 mM
sucrose for 15 minutes, and 0.1 M glycine was added for 15
minutes. Cells were permeabilized for 15 minutes with 0.15%
TritonX-100 and 1% BSA in PBS. Cells were washed again
twice with PBS. Duolink blocking solution was added to the
cells and incubated at 37°C for 30 minutes in a humidity
chamber. Blocking solution was removed and primary antibody,
diluted in antibody diluent, was applied to the cells overnight at
4°C in a humidity chamber. Cells were washed three times in
PLA wash buffer A prior to PLA probe addition for one hour at
37°C in a humidity chamber. Cells were washed twice with PLA
wash buffer A prior to ligase addition for thirty minutes at 37°C
in a humidity chamber. Cells were washed again twice before
addition of polymerase solution for 100 minutes at 37°C in a
humidity chamber. Cells were washed twice in PLA wash buffer
B and once in 0.01X PLA wash buffer B. Coverslips were then
mounted in Vectashield with Dapi and sealed with clear nail
polish. Confocal microscopy was performed on a Zeiss 710
Confocal Laser Scanning Microscope at 63x. Z-stacks were
captured, and BlobFinder (Sweden) software was used to
analyze PLA data.
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